EFECTO DEL BENZNIDAZOL SOBRE ENZIMAS DE BIOTRANSFORMACIÓN Y TRANSPORTADORES DE DROGAS QUE AFECTAN SU PROPIA BIODISPONIBILIDAD

RIGALLI JP; PERDOMO VG; MOTTINO AD; RUIZ ML; CATANIA VA

Revista Farmacéutica

Academia Nacional de Farmacia y Bioquímica

Lugar: Buenos Aires; Año: 2014 vol. 156

0034-9496

Benznidazole (BZL) constitutes the therapeutic agent of choice for treatment of Chagas disease in endemic regions and during its acute phase. During BZL Therapy, drugdrug interactions, generation of BZL toxic metabolites, or changes in BZL metabolism or pharmacokinetics may occur. These undesirable effects are poorly characterized at present. We here reviewed most relevant data demonstrating up-regulation of expression and activity of phase I and II biotransformation systems and drug export pumps, which take place either in liver or intestine. Based on these effects it is possible to predict the occurrence of drugdrug interactions with therapeutic agents coadministered with BZL, as well as a decrease in BZL therapeutic efficacy, particularly under chronic treatment conditions.